Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02710396
Title Genetic Predictors of Benefit to Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Columbia University
Indications

head and neck cancer

bladder urothelial carcinoma

esophagus squamous cell carcinoma

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Laura & Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016 United States Details
Columbia University New York New York 10032 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field